RAAS inhibitors in the cardiovascular continuum: What is still missing

Cardiovascular Drugs and Therapy

Volumn 18, Issue 4, 2004, Pages 311-320

  Maggioni, Aldo P ^a   Latini, Roberto ^b  

^a ANMCO RESEARCH CENTER   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

ACEIs; ARBs; cardiovascular; clinical trials; RAAS

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; NORADRENALIN; RAMIPRIL; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SAMPLE SIZE; STROKE; SURVIVAL RATE; TASTE DISORDER;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; META-ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 4544255098     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CARD.0000041251.82015.91     Document Type: Review

References (98)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-1435.
2. Fletcher RD, Cintron GB, Johnson G, et al. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. Circulation 1993;87:V149-V155.
3. Nauman D, Greenberg B. Studies of Left Ventricular Dysfunction (SOLVD). Am. J Geriatr Cardiol 1993;2:28-36.
4. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
5. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Charm-Programme Investigators. J Card Fail 1999;5:276-282.
6. Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press 2001;10:83-91.
7. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. NEJM 2003;349:1893-1906.
8. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-1421.
9. Greenberg BH. Angiotensin receptor blockers in heart failure: A work in progress. J Am Coll Cardiol 2002;40:1422-1424.
10. Weber MA. Angiotensin receptor blockers and the cardiovascular continuum: What future is indicated by recent successes? Eur Heart J Suppl 2003;5:C1-C4.
11. Charlton BG. Mega-trials: Methodological issues and clinical implications. J R Coll Physicians Lond 1995;29:96-100.
12. Charlton BG. Mega-trials: Methodological issues and clinical implications. J R Coll Physicians Lond 1995;29:96-100.
13. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
14. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
15. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. (MERIT-HF). JAMA 2000;283:1295-1302.
16. Enserink M. Bioethics. Helsinki's new clinical rules: Fewer placebos, more disclosure. Science 2000;290:418-419.
17. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 2000;133:455-463.
18. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
19. Sever P. The SCOPE trial. Study on Cognition and Prognosis in the Elderly. J Renin Angiotensin Aldosterone Syst 2002;3:61-62.
20. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
21. Packer M, Fowler MB, Roecker EB, et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on morbidity of patients with severe chronic heart failure. N Engl J Med 2001;344:1659-1667.
22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
23. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
24. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
25. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
26. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
27. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
28. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-2458.
29. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
30. Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-975.
31. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996;125:605-613.
32. Fleming TR. Surrogate end points in cardiovascular disease trials. Am Heart J 2000;139:S193-S196.
33. Lipicky RJ, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993;22:179A-184A.
34. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414-1421.
35. Piller LB, Davis BR, Cutler JA, et al. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 2002;3:10.
36. Gavras I, Gavras H. Benefits and side effects of blood pressure lowering treatment: What was wrong with doxazosin in the ALLHAT? Curr Control Trials Cardiovasc Med 2001;2:257-259.
37. D'Agostino RB Jr. Debate: The slippery slope of surrogate outcomes. Curr Control Trials Cardiovasc Med 2000;1:76-78.
38. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991;121:1244-1263.
39. Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens Suppl 1997;15:S31-S36.
40. Weber MA. The angiotensin II receptor blockers: Opportunities across the spectrum of cardiovascular disease. Rev Cardiovasc Med 2002;3:183-191.
41. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
42. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-1886.
43. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-766.
44. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
45. Haffner S, Holman R, Califf R, et al. Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. Presented at the 38th Annual of the European Association for the Study of Diabetes. Budapest, Hungary, Sept. 3, 2002.
46. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
47. Desouza C, Gilling L, Fonseca V. Management of the insulin resistance syndrome. Curr Diab Rep 2001;1:140-147.
48. Khamaisi M, Wainstein J, Hancu N, et al. Association of hyperglycemia and insulin with diabetic cardiovascular complications. Isr Med Assoc J 2003;5:116-119.
49. Goff DC Jr, Zaccaro DJ, Haffner SM, et al. Insulin sensitivity and the risk of incident hypertension: Insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2003;26:805-809.
50. Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-899.
51. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000;321:412-419.
52. Holman R. The UKPDS: Implications for the dyslipidaemic patient. Acta Diabetol 2001;38:S9-S14.
53. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
54. Strain WD, Chaturvedi N. The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst 2002;3:243-246.
55. Velasquez MT, Bhathena SJ, Striffler JS, et al. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism 1998;47:7-11.
56. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36:449-467.
57. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
58. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
59. Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001;2:298-306.
60. Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. J Hum Hypertens 1999;13:337-342.
61. Rangarajan U, Kochar MS. Hypertension in women. WMJ 2000;99:65-70.
62. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
63. LeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-542.
64. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-1060.
65. Egger M, Smith GD, Sterne JA. Uses and abuses of metaanalysis. Clin Med 2001;1:478-484.
66. Baigent C. The need for large-scale randomized evidence. Br J Clin Pharmacol 1997;43:349-353.
67. Woods KL. Mega-trials and management of acute myocardial infarction. Lancet 1995;346:611-614.
68. Dernol P, Hubner GE, Weihrauch TR. On the value of large multicenter drug intervention trials. Arzneimittelforschung 1997;47:985-989.
69. Heng D. Megatrials of drug treatments: Strengths and limitations. Ann Acad Med Singapore 2000;29:606-609.
70. Smith GD, Egger M. Meta-analysis: Unresolved issues and future developments. BMJ 1998;316:221-225.
71. Robertson JI. Which antihypertensive drug classes have been shown to be beneficial? What are their benefits? A critique of hypertension treatment trials. Cardiovasc Drugs Ther 2000;14:357-366.
72. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
73. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:2202-2212.
74. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581.
75. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol 1988;62:41A-45A.
76. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
77. Fleischmann EH, Schmieder RE. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep 2002;4:474-178.
78. Furukawa TA, Streiner DL, Hori S. Discrepancies among megatrials. J Clin Epidemiol 2000;53:1193-1199.
79. Pitt B, Yusuf S, for the SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD): Subgroup results. J Amer Coll Cardiol 1992;19:215A.
80. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-119.
81. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients. J Amer Coll Cardiol 2000;35:1801-1807.
82. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: A systematic review. Lancet 2002;360:1037-1043.
83. Takkouche B, Etminan M, Caamano F, et al. Interaction between aspirin and ACE Inhibitors: Resolving discrepancies using a meta-analysis. Drug Saf 2002;25:373-378.
84. Zanchetti A, Hansson L, Leonetti G, et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002;20:1015-1022.
85. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients. J Amer Coll Cardiol 2000;35:1801-1807.
86. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: A systematic review. Lancet 2002;360:1037-1043.
87. Takkouche B, Etminan M, Caamano F, et al. Interaction between aspirin and ACE Inhibitors: Resolving discrepancies using a meta-analysis. Drug Saf 2002;25:373-378.
88. Zanchetti A, Hansson L, Leonetti G, et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002;20:1015-1022.
89. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993;329:1615-1622.
90. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992;339:753-770.
91. Fresco C, Avanzini F, Bosi S, et al. Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per Io Studio della, Sopravvivena nell'Infarto Miocardico. J Hypertens 1996;14:743-750.
92. Sacristan JA, Galende I. Clinical Trials. Randomised database studies could serve as new strategy. BMJ 1999; 318:1138.
93. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001;19:1139-1147.
94. Velazquez EJ, Douglas Weaver D, Armstrong PW, et al. Heart failure and/or left ventricular systolic dysfunction complicating myocardial infarction is common and accounts for the majority of in-hospital myocardial infarction mortality: Results of the VALIANT registry. Suppl J Am Coll Cardiol 2002;41:148A.
95. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999;20:1182-1190.
96. Winer N, Sowers JR. Cardiovascular risk factors in diabetic patients with hypertension. Curr Diab Rep 2002;2:263-266.
97. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2001;104:2996-3007.
98. Treatment of Hypertension in Adults with Diabetes. American Diabetes Association 2003;26(Suppl. 1):580-582.